DAPT-MVD: Extended DAPT reduces MACCE in patients with multi-vessel disease after DES
Key Points: The optimal duration and choice of dual antiplatelet therapy (DAPT)…
BETTER-BP: Offering Cash Incentives Improves Anti-Hypertensive Medication Adherence, But Not Blood Pressure Control
Key Points: Adherence to antihypertensive medications remains a persistent challenge in clinical…
OCEAN: Ongoing Anticoagulation May Not be Necessary After 1-year Post Successful AF Ablation
Key Points: Atrial fibrillation (AF) increases the risk of stroke, and long-term…
VESALIUS-CV: PCSK9-Inhibitor Evolocumab Reduces MACE for Primary Prevention
Key Points: PCSK9-inhibitors – including evolocumab – are highly effective LDL-C–lowering medications…
DR10624, a First-in-Class FGF21/GLUCAGON/GLP-1 Receptor Triple Agonist, Significantly REDUCED Triglycerides, Lipids, and Liver Fat in Patients with Severe HYPERTRIGLYCERIDEMIA
Key Points: DR10624 is a first-in-class triple agonist of the FGF21, glucagon,…
NEWTON-CABG: Evolocumab Did Not Improve Vein Graft Patency After CABG
Key Points: Saphenous vein graft (SVG) failure is common after coronary artery…
Essence-TIMI 73b: Olezarsen Safely and Effectively Reduces Triglycerides in Patients With Moderate Hypertriglyceridemia and High CV Risk
Key Points: Olezarsen, an anti-sense oligonucleotide targeting APOC3 mRNA, is approved to…
VICTOR: Vericiguat Did Not Meet Primary Endpoint But Reduced CV Death in Stable, Ambulatory HFrEF
Key Points: The VICOTRIA trial previously demonstrated that vericiguat reduced the risk…
VICTOR + VICTORIA: Vericiguat Showed Benefits Across the Spectrum of HFrEF Severity
Key Points: VICTORIA and VICTOR and were randomized trials that evaluated vericiguat…
SUMMIT: Tirzepatide Improved Renal Function in Patients with HFpEF, Obesity, and CKD
Key Points The SUMMIT randomized control trial demonstrated that tirzepatide significantly reduced…
EKSTROM Trial: Low-dose Colchicine Reduced Total Plaque Volume on CCTA, but Not Low Attenuation Plaque
Key Points The COLCOT trial demonstrated colchicine improved coronary plaque characteristics in…
GCVRC: Controlling Hypertension and Stopping Smoking at Midlife Associated With Greatest Gains in Additional Life-years Free of CVD
Key Points Five classic risk factors – HTN, DM, HLD, underweight/obesity, and…
ALLEPRE: Fully Nursing-Led Heart Health Counseling Program Reduces CV Outcomes After ACS
Key Points Nurses are increasingly responsible for cardiovascular risk management, but randomized…
HOST-BR: 3 Months Of DAPT Might be Reasonable For Both Low- And High-Bleeding Risk Patients After PCI With DES
Key Points After DES placement, guidelines recommend considering shorter DAPT duration (e.g.…
SOUL: Oral Semaglutide Reduced CV Events In High-Risk Patients With T2DM with ASCVD or CKD
Key Points Injectable semaglutide, a GLP-1 receptor agonist, reduces CV events in…